Global Blood Therapeutics, Inc. — Net Income by Fiscal Year
9 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/6a840c5d-f260-4a87-b1ab-3d0ac28584ff/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2021 | $-303.1M | 2021-01-01 – 2021-12-31 | evidence 0000950170-22-001781 |
| FY 2020 | $-247.6M | 2020-01-01 – 2020-12-31 | evidence 0001193125-21-054629 |
| FY 2019 | $-266.8M | 2019-01-01 – 2019-12-31 | evidence 0001193125-20-050084 |
| FY 2018 | $-174.2M | 2018-01-01 – 2018-12-31 | evidence 0001193125-19-054260 |
| FY 2017 | $-117.0M | 2017-01-01 – 2017-12-31 | evidence 0001193125-18-060818 |
| FY 2016 | $-82.5M | 2016-01-01 – 2016-12-31 | evidence 0001193125-17-080322 |
| FY 2015 | $-46.4M | 2015-01-01 – 2015-12-31 | evidence 0001629137-16-000028 |
| FY 2014 | $-20.8M | 2014-01-01 – 2014-12-31 | evidence 0001629137-16-000028 |
| FY 2013 | $-18.1M | 2013-01-01 – 2013-12-31 | evidence 0001629137-16-000028 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Global Blood Therapeutics, Inc. — all facts · Revenue · Operating Income